Increasing bacterial resistance to classical antibiotics remains a serious threat and urges the development of novel pathogen-killing strategies. Exploiting bacterial communication mechanisms such as quorum sensing (QS) is a promising strategy to specifically target certain pathogens. The major aim of this project is the introduction of a genetic circuit enabling Bacillus subtilis to actively detect, attach to, and eventually kill Staphylococcus aureus and Streptococcus pneumoniae.
Initially, we will introduce the autoinducer-sensing two-component systems of S. aureus and S. pneumoniae into B. subtilis to create a pathogen-detecting strain. By utilizing QS-dependent promoters, we will then trigger pathogen-killing strategies like the production of antimicrobial peptides or biofilm degradation. As a safety measure, a delayed suicide-switch guarantees non-persistence of genetically modified B. subtilis in the absence of pathogens. We envision the use of BaKillus as a smart, cheap and simple-to-use medical device for diagnostics and targeted treatment of multiresistant superbugs.
Sensing
This part of the BaKillus-concept focuses on specific pathogen detection. Here we use quorum sensing to specifically recognize the presence of certain pathogens. The major aim of this subproject is transferring the quorum sensing two-component systems AgrC-II/AgrA of Staphylococcus aureus and ComDE of Streptococcus pneumoniae into Bacillus subtilis, thus creating a pathogen detecting strain. With this strategy we will trigger our killing strategies only if a threshold concentration of autoinducers, produced by pathogens, is present in the environment. Thereby we aim to drastically increase the specificity of our antimicrobial strategies compared to commonly used broad-spectrum antibiotic therapy.
Staphylococcus aureus
Virulence of S. aureus
S. aureus is living as a commensal in humans with a prevalence of up to 30% of the population in Europe [http://www.nivel.nl/sites/default/files/ECCMID%202013%20-%20Resistance%20results_0.pdf (1)]. It is also responsible for a variety of diseases ranging from skin infections to life threatening toxinosis and is quickly adapting to the use of common antibiotics by becoming resistant.
This dual lifestyle and the expression of a multitude of virulence factors is tightly regulated by a process termed quorum sensing [http://jb.asm.org/content/193/21/6020 (2)].
Quorum sensing in S. aureus
Quorum Sensing is a mechanism of bacterial cell-cell communication, granting bacteria the ability to measure the density of their surrounding cell population, and react to this by upregulation of specific genes.
In ‘’S. aureus’’ this process is one of the major regulator of its virulence, making sure that energy-costly virulence factors are only produced when a large enough number of pathogens is present to overcome host-defence mechanisms.
In this mechanism a certain peptide termed autoinducing peptide (AIP) is produced from a pro-peptide called AgrD and further processed and exported by a membrane protein AgrB to create a cyclic AIP. When a certain threshold concentration of AIP in the environment is reached, AIPs activate the receptor-histidine kinase AgrC.
Upon induction AgrC phosphorylates the intracellular response regulator AgrA with its cytosolic histidine kinase domain [http://www.annualreviews.org/doi/abs/10.1146/annurev.genet.42.110807.091640 (3) ]. Phosphorylated AgrA then binds to distinct sites in the P2 and P3 promoter-region and activates these promoters. [http://jb.asm.org/content/193/21/6020 (2)]
The P2 promoter activates transcription of the agrBDCA-Operon and thereby represents a positive feedback-loop. The P3 promoter activates transcription of the RNA-III transcript, involved of virulence gene expression [http://jb.asm.org/content/182/22/6517.full (4)]).
Fig.1: Quorum sensing in Staphylococcus aureus. Taken from Novick and Geisinger, "Quorum Sensing in Staphylococci", Annual Review of Genetics, Vol. 42: 541-564 (2008)
Interestingly, accumulated mutations in the hypervariable region of the agrBDCA-operon have led to four different pherotypes of S. aureus, using different AgrC-types, and producing different AIPs (AIPI, AIPII, AIPIII, AIPIV), which cross-inhibit each other and might correlate with certain diseases associated with S. aureus [http://www.sciencemag.org/content/287/5452/391.full.html (5)].
For this project we used genomic DNA derived from the strain Staphylococcus aureus N315, which is a MRSA strain, belonging to the AIP-II group.
Streptococcus pneumoniae
Virulence of S. pneumoniae
All over the world, Streptococcus pneumoniae causes the life threating invasive diseases pneumonia, sepsis and meningitis. In early childhood the diplococcus colonizes the epithelium of the upper respiratory tract as a commensal bacterium. Under certain circumstances, it gets a threat by tissue invasion. Still up to date, not much is known regarding the mechanism behind the shifting from a colonizer organism to an invader or how S. pneumoniae is able to cross the blood-brain barrier to cause meningitis.[http://www.ncbi.nlm.nih.gov/pubmed/19880020]
To cross the line from an opportunist to a pathogen, S. pneumoniae needs to express specific virulence factors in a coordinated way. Apart from virulence factors like the polysaccharide capsule, the pore forming toxin pneumolysin or surface proteins like PspA and PspC, also biofilm production plays an important role for persistence in the human nasopharynx and contributes to pneumonia and meningitis [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1618759/].
One aspect of its infectiousness is the ability to perform natural transformation. Thus, it can take up extracellular DNA containing the information for resistance against diverse antibiotics and permanently incorporate the DNA into its genome via recombination. The main problem of treating S. pneumoniae infections is the increasing spread of ß-lactam resistance. Luckily, the molecular mechanism behind natural transformation in S. pneumoniae is the focus of current research.
Natural Transformation in S. pneumoniae
In S. pneumoniae, biofilm production and competence for natural genetic transformation are triggered by a two component regulatory system, responsive to environmental stimuli. There, a peptide pheromone called competence-stimulating-peptide (CSP) binds to and consequently activates the membrane-embedded sensor kinase ComD by changing the conformation of the polytopic kinase. ComD autophosphorylates and subsequently transphosphorylates the cognate response regulator ComE. ComE acts as transcription activator via binding to the -10 promoter regions of early and late competence genes. These ComE binding sites (CEbs) consist of a 9 bp direct repeat seperated by a stretch of 12 nucleotides.
Fig. 2: Competence regulation in Streptococcus pneumoniae. See text for more details. (Jonsborg et al. 2009)
A positive feedback loop ensures the availability of the two component system by activating the expression of the comCDE operon, where comDE encodes for the two component system ComDE and comC for the precursor peptide pre-CSP. Pre-CSP is cleaved to the mature peptide pheromone and transported to the extraplasmic room by the ABC transporter ComAB, whose expression is also activated by ComE. [http://www.ncbi.nlm.nih.gov/pubmed/?term=regulation+of+natural+genetic+transformation+and+acquisition+of+transforming+DNA].
In addition, ComE~P is able to trigger the expression of comX and comW , encoding for the alternative σ-factor X, and its stability factor ComW. This alternative σ-factor is required for the transcription of the so called late competence genes involved in the process of DNA uptake and recombination.
We are working with the genomic DNA of the nonencapsulated apathogenic strain R6 of S. pneumoniae, whose genome is completely sequenced [http://www.ncbi.nlm.nih.gov/pubmed/11544234]. CSP is a 17 amino acid long linear protein with the following amino acid sequence: Glu-Met-Arg-Leu-Ser-Lys-Phe-Arg-Asp-Phe-Ile-Leu-Gln-Arg-Lys-Lys-OH [http://www.microbesonline.org/cgi-bin/fetchLocus.cgi?locus=134925&disp=4]with a charged N-terminal residue and a positively charged C-terminal tail [http://www.ncbi.nlm.nih.gov/pubmed/16484185].
Sources
[5] van der Poll, T., & Opal, S. M. (2009). Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet, 374(9700), 1543-1556. doi: 10.1016/S0140-6736(09)61114-4
[6] Oggioni, M. R., Trappetti, C., Kadioglu, A., Cassone, M., Iannelli, F., Ricci, S., . . . Pozzi, G. (2006). Switch from planktonic to sessile life: a major event in pneumococcal pathogenesis. Mol Microbiol, 61(5), 1196-1210. doi: 10.1111/j.1365-2958.2006.05310.x
[7] Johnsborg, O., & Havarstein, L. S. (2009). Regulation of natural genetic transformation and acquisition of transforming DNA in Streptococcus pneumoniae. FEMS Microbiol Rev, 33(3), 627-642.
[8] Hoskins, J., Alborn, W. E., Jr., Arnold, J., Blaszczak, L. C., Burgett, S., DeHoff, B. S., . . . Glass, J. I. (2001). Genome of the bacterium Streptococcus pneumoniae strain R6. J Bacteriol, 183(19), 5709-5717. doi: 10.1128/JB.183.19.5709-5717.2001
[9] Sequence obtained from http://www.microbesonline.org
[10] Johnsborg, O., Kristiansen, P. E., Blomqvist, T., & Havarstein, L. S. (2006). A hydrophobic patch in the competence-stimulating Peptide, a pneumococcal competence pheromone, is essential for specificity and biological activity. J Bacteriol, 188(5), 1744-1749. doi: 10.1128/JB.188.5.1744-1749.2006
To induce the quorum sensing module of S. aureus and S. pneumoniae into BaKillus, two different parts had to be transferred to B. subtilis: First, the two component system AgrCA of S. aureus or ComDE of S. pneumoniae need to be established for B. subtilis to sense and respond to the quorum sensing molecules of the specific pathogen. As a second step, the QS-activated promoters (PQS) need to be transformed into B. subtilis to trigger the expression of our killing factors.
For evaluation, the QS-dependent promoters were cloned in front of the lux-reporter cassette of the vector [http://parts.igem.org/wiki/index.php?title=Part:BBa_K823025 pBS3C-lux] from the Bacillus BioBrickBox of the iGEM LMU team 2012.
QS Two Component System
The two component system [http://parts.igem.org/Part:BBa_K1351036 agrCII-A] for S. aureus has been designed as a composite part derived from Staphylococcus aureus N315 gDNA.
The two intermediated parts agrC-II and agrA were amplified by PCR using primers with modified RFC25 prefix and suffix. And then fused by using the restriction sites EcoRI and SpeI for agrC-II, as well as XbaI and PstI for agrA, thus creating the composite part [http://parts.igem.org/Part:BBa_K1351036 agrCII-A].
The operon encoding for the histidine sensor kinase ComD and the response regulator ComE comDE for S. pneumoniae sensing was designed in two different ways: On one hand, the native comDE operon with its native ribosome binding site (RBS) ([http://parts.igem.org/Part:BBa_K1351015 BBa_K1351015]), on the other hand thecomDE operon with the B. subtilis adapted RBS (TAAGGAGG) in the BioBrick standard RFC25 ([http://parts.igem.org/Part:BBa_K1351016 BBa_K1351016]). Unfortunately, the operon contains two EcoRI and one SpeI restriction site. The attempts to mutagenize these restriction sites were not completed successfully in time as one recognition site remained. Thus, the comDE operon could not been sent to the registry - but this will be accomplished as soon as possible.
QS dependent Promoters
In S. aureus, the AgrA-sensitive promoters P2 [http://parts.igem.org/Part:BBa_K1351037 BBa_K1351037] and P3 [http://parts.igem.org/Part:BBa_K1351038 BBa_K1351038] with four AgrA binding sites downstream of the -35 signals were used for evaluation. The intergenic region with suspected regulator binding sites is shown in Fig. 3
Fig. 3: AgrA dependent promoters P2 and P3 with the intergenic region containing several regulator binding sites for AgrA (arrows) and SarA/R (dashed lines) (figure taken from Reyes et al. 2000)
For S. pneumoniae sensing, the two ComE dependent promoters PcomC [http://parts.igem.org/Part:BBa_K1351024 BBa_K1351024] and PcomAB [http://parts.igem.org/Part:BBa_K1351025 BBa_K1351025] and additional promoters containing putative ComE binding sites (CEbs) PmreA, PnatAB) were taken for evaluation (see figure 4).
Fig. 4: ComE dependent promoters containing bases matching (blue) and differing (red) from the CEbs consensus sequence. (figure modified from Martin et al. 2013)
To test the functionality of our model, first, the two component system was cloned into the integrative vector [http://parts.igem.org/wiki/index.php?title=Part:BBa_K823027 pBS2E] from the Bacillus BioBrick Box under the control of Pxyl, an inducible promoter that responds to extracellular xylose (see fig. A). The corresponding QS-dependent promotor was cloned in the vector [http://parts.igem.org/wiki/index.php?title=Part:BBa_K823025 pBS3C-lux], thus fused to luxABCDE. If QS-molecules are detected from the two component system, PQS will trigger the expression of luxABCDE, resulting in luminescence which was measured by a multi-mode plate reader (18 hrs, 37 °C, shaking).
In the distant future, the quorum sensing two component system, under the regulation of an inducible promoter, will be combined with an quorum sensing promoter expressing specific killing factors (see fig. B).
S. aureus Sensing
We constructed the biobrick <bbpart>BBa_K316036</bbpart> encoding for a composite part containing the AIP-II sensing two component system AgrC-IIA
[http://parts.igem.org/wiki/index.php/Part:BBa_K316036]
And the AIP-II sensing dependant promoters P2 and P3 <bbpart>BBa_K316037</bbpart>, <bbpart>BBa_K316038</bbpart> P2 [http://parts.igem.org/wiki/index.php/Part:BBa_K316037]
and P3 [http://parts.igem.org/wiki/index.php/Part:BBa_K316038]
As a first step we recorded the promoter backgrounds of the P2 and P3 promoters with a luminescence reporterassay, using the strategy outlined in design. (Fig.3)
As expected according to the strength of the -35 and -10 signals, P2 is the stronger promoter showing a higher background, compared to P3.
In a next step we induced the expression of PxylA-agrCII-A by adding 0%, 0.02%, 0.2% Xylose at an OD600 of about 0.1.
The result is depicted in Figure 4. The result is in accordance with our expactations since strong overexpression of the two-component system should lead to unspecific induction of the P2 and P3 promoters, and thereby can be used as a method to measure relative expression of agrC-IIA.
Fig.4: Luminescence Reporterassay of the strain W168 lacA::PxylA-agrCA; sacA::P2/P3-luxABCDE
Using the strategy outlined in design, we tried to induce the AgrC-IIA two-component system, with synthetic AIP-II. The synthetic peptids have been dissolved in 100% DMSO to 1 mM concentration and further diluted in dH20.
The constructs have then been induced with a range of different concentrations of AIP-II at an OD600 of 0.1.
The result is shown in Figure 4. Unfortunatly we were not able to show induction of the system by addition of AIP-II. Several other approaches like the addition of a protease inhibitor cocktail to the growth media, several washing steps, using LB instead of MCSE or inducing with 50 µM AIP-II did not change this observation.
Fig.4: Luminescence Reporterassay of the strain W168 lacA::PxylA-agrCA; sacA::P2/P3-luxABCDE induced with AIP-II
There are several possible reasons why the induction didn't work as expected. One idea is that the extracellular proteases produced by Bacillus subtilis destroy the synthetic AIPs. So we tried adding protease inhibitor cocktails to the growth media and using the protease deficient strain Bacillus subtilis WB700. We successfully transformed the WB700 strain with the reporter construct pBS4S-PxylA-agrCA. However the reporter constructs pBS3C-P2/P3-luxABCDE refused transformation.
All in all this set of constructs needs several further protocol optimisations and testing.
S. pneumoniae Sensing
First, we optimized the BioBrick <bbpart>BBa_K316018</bbpart> encoding for the comC promoter [http://parts.igem.org/wiki/index.php/Part:BBa_K316018] by sending our BioBrick <bbpart>BBa_K1351024</bbpart> to the registry. For the previous version, no DNA was available.
The BIG result we obtained in the night of the wiki freeze performing a luminescence assay with different constructs in B. subtilis Pxyl - comDE PQS - lux based on [http://parts.igem.org/Part:BBa_K1351016 BBa_K1351016]. Three different PQS were tested: PcomC, PcomAB, PmreA. The comDE operon expression was induced with 0 %, 0,02 % and 0,2 % xylose. Adding 0 mg/ml CSP, 100 mg/ml CSP and 1000 mg/ml CSP luxABCDE expression is only activated if B. subtilis was able to sense CSP due to the comDE operon.
For PmreA, no significant luminescence output could be measured concerning differing CSP concentrations. Nevertheless, at a xylose concentration of 0,02 % and induction of 1000 mg/ml CSP PcomC and PcomAB showed a 3 fold increased luminescence output compared with an induction of 0 mg/ml and 100 mg/ml CSP.
These results were obtained with cultures growing in MCSE medium two hours after induction with CSP. A concentration of 0.02 % xylose was optimal to measure CSP dependent luminescence.
Adhesion
As part of the BaKillus strategy, we want to reduce the selective pressure on non-pathogenic bacteria to prevent resistance development. Towards this end, BaKillus is equipped with pathogen-binding peptides on its surface, thereby adhering specifically to the targeted bacteria. This approach ensures high local concentration of killing factors while minimizing harmful effects on untargeted species.
Surface display of the pathogen-binding peptides is achieved by translational fusions to naturally occurring surface proteins of B. subtilis. Cell-wall binding modules of autolysins are used for non-covalent interaction with the B. subtilis cell wall, whereas a sortase-based system functions via covalent attachment to the cell wall. In both cases, a linker between cell wall anchor and peptide allows flexibility of the fusion protein and increases its range. Peptides binding to different receptors on the surface of pathogens mediate specific binding.
Surface display
Bacterial cell surfaces are covered with a wide range of proteins functioning as transporters, interacting with molecules and cells or fulfilling a variety of other functions. As they are naturally displayed on the cell’s surface, they can also be used for presenting heterologous proteins or peptides.
One class of proteins that have been used for surface display are B. subtilis autolysins, in particular LytC and LytE [1, 2]. Autolysins hydrolase peptidoglycan and thus play a role in cell wall turnover, vegetative growth and cell division. They consist of an N-terminal cell wall binding (CWB) domain with a signal peptide directing export via the Sec pathway and of a C-terminal catalytic domain [3, 4]. Fusions of the CWB domains of LytC and LytE to heterologous proteins have been shown to successfully facilitate surface display of their passenger protein in B. subtilis [1, 2].
Another promising system is based on the B. subtilis sortase YhcS and its substrate YhcR. Sortases represent a class of membrane-anchored proteins in gram-positive bacteria, which recognize their substrates via a conserved C-terminal pentapeptide sequence. They catalyze covalent binding of their substrates to lipid II, an intermediate of peptidoglycan synthesis [5]. Two putative sortase-substrate pairs have been identified in B. subtilis, one of them being YhcS/YhcR, which has already been used for successful surface display of recombinant proteins [5, 6].
Pathogen-binding peptides
Bacterial adhesins mediate binding of the cells to all kind of surfaces, thereby preventing removal by physical influences like sheer forces. Attachment of pathogens to their host is often crucial for infection, which is why many adhesins are listed as virulence factors [7]. Binding partners of adhesins are often components of the extracellular matrix, which would be difficult to express on the BaKillus surface. In contrast, proteins of human cells that get bound by adhesins are optimal candidates for translational fusions to surface display systems. BaKillus mimics human cells by expressing parts of the proteins on its surface, leading to binding of the pathogens to BaKillus. Barbu et. al. 2010 [8] and Muchnik et. al. 2013 [9] used phage display to identify the binding peptide interaction partners of Staphylococcus aureus virulence factor SdrC and Streptococcus pneumoniae adhesin NOX, respectively. Those peptides are the specific binding sequences of SdrC and NOX within surface proteins of human cells. Thus, expression of the peptides on the BaKillus surface should enable it to adhere to the targeted pathogens.
Sources
1. Chen, C.L., et al., Development of a LytE-based high-density surface display system in Bacillus subtilis. Microb Biotechnol, 2008. 1(2): p. 177-90.
2. Kobayashi, G., et al., Accumulation of a recombinant Aspergillus oryzae lipase artificially localized on the Bacillus subtilis cell surface. J Biosci Bioeng, 2000. 90(4): p. 422-5.
3. Tjalsma, H., et al., Signal peptide-dependent protein transport in Bacillus subtilis: a genome-based survey of the secretome. Microbiol Mol Biol Rev, 2000. 64(3): p. 515-47.
4. Smith, T.J., S.A. Blackman, and S.J. Foster, Autolysins of Bacillus subtilis: multiple enzymes with multiple functions. Microbiology, 2000. 146(2): p. 249-262.
5. Nguyen, H.D., T.T. Phan, and W. Schumann, Analysis and application of Bacillus subtilis sortases to anchor recombinant proteins on the cell wall. AMB Express, 2011. 1(1): p. 22.
6. Liew, P.X., C.L. Wang, and S.L. Wong, Functional characterization and localization of a Bacillus subtilis sortase and its substrate and use of this sortase system to covalently anchor a heterologous protein to the B. subtilis cell wall for surface display. J Bacteriol, 2012. 194(1): p. 161-75.
7. Coutte, L., et al., Role of Adhesin Release for Mucosal Colonization by a Bacterial Pathogen. The Journal of Experimental Medicine, 2003. 197(6): p. 735-742.
8. Barbu, E.M., et al., beta-Neurexin is a ligand for the Staphylococcus aureus MSCRAMM SdrC. PLoS Pathog, 2010. 6(1): p. e1000726.
9. Muchnik, L., et al., NADH oxidase functions as an adhesin in Streptococcus pneumoniae and elicits a protective immune response in mice. PLoS One, 2013. 8(4): p. e61128.
For cloning and evaluation, the adhesion project was divided into its two main components ‘surface display’ and ‘pathogen binding’. BioBricks were generated for the pathogen-specific peptides as well as for the parts necessary for surface display.
Surface Display
Constructs for non-covalent and covalent surface display were cloned similar to those described by Chen et. al., 2008 [1], and Liew et. al., 2012 [6], respectively.
As depicted in figure 1A, cell-wall binding domains (CWB) of LytC or LytE ([http://parts.igem.org/wiki/index.php?title=Part:BBa_K1351006 BBa_K1351006] or [http://parts.igem.org/wiki/index.php?title=Part:BBa_K1351007 BBa_K1351007]) were translationally fused to a protein of interest for non-covalent anchoring of the latter to the cell wall. These CWB domains also included the native signal peptide (SP) of the respective proteins to direct export via the Sec pathway. For covalent anchoring, signal peptide ([http://parts.igem.org/Part:BBa_K1351008 BBa_K1351008]) and cell wall anchoring domain (CWAD, [http://parts.igem.org/Part:BBa_K1351010 BBa_K1351010]) of the sortase substrate YhcR and a 57 amino acid linker ([http://parts.igem.org/Part:BBa_K1351009 BBa_K1351009]) were assembled with the protein of interest as depicted in figure 1B to generate a YhcR-like fusion.
To evaluate the functionality of the constructs, the latter were cloned into the replicative B. subtilis vector pBS0K under the control of the inducible promoter Pspac. Two different proteins were used to test for successful display: Firstly, a superfolder GFP variant (sfGFP) was used for fluorescence microscopy to check if the constructs locate to the cell wall as shown in figure 2. This variant of GFP had been shown previously to fold in the periplasm of gram-negative bacteria [10] and could thus be expected to be fuctional also in the extracellular environment, in contrast to normal GFP that does not fold under reducing conditions. As controls for the sfGFP constructs, only the signal peptides without the respective cell wall binding or anchoring domains were fused to sfGFP, which should lead to secretion of the fusion into the growth medium.
Secondly, fusions to alkaline phosphatase (PhoA) were used to detect surface accessibility of the presented protein, as PhoA is only active when exported out of the cytoplasm [11]. Agar plates containing the PhoA substrate XP (5-bromo-4-chloro-3-indolyl-phosphate) indicate enzyme activity by turning blue where the substrate is hydrolyzed and further oxidized to an indigo dye [12]. PhoA was also fused to intracellular GFP as a negative control and to an extracellular domain of LiaI as a positive control. The PhoA-deficient B. subtilis strain MH3402 was used for expression of all PhoA constructs.
Pathogen binding
Binding of BaKillus to pathogens in general, and for this project to S. aureus and S. pneumoniae in particular, should be mediated by specific peptides that had been identified via phage display. Unfortunately, evaluation of the S. aureus-specific peptide Nrx1b ([http://parts.igem.org/Part:BBa_K1351000 BBa_K1351000]) was not possible due to the lack of an S2 laboratory, as the Nrx1b-binding partner SdrC is a virulence factor of S. aureus.
Evaluation of peptides binding to S. pneumoniae was done by a biochemical pull-down assay with their binding partner NADH oxidase (NOX). As shown in figure 3, NOX was bound to streptavidin-coupled beads via an N-terminal fused Strep-Tag II, for which the pASK-IBA expression vector system was used. S. pneumoniae-specific peptides C4P, CSP and L5P ([http://parts.igem.org/Part:BBa_K1351001 BBa_K1351001], [http://parts.igem.org/Part:BBa_K1351002 BBa_K1351002] and [http://parts.igem.org/Part:BBa_K1351003 BBa_K1351003], respectively) were fused C-terminally to a maltose-binding protein (MBP) and a 6xHis-tag. The MBP prevents degradation of the short peptides by proteases and was used for detection of the peptide fusions on an SDS gel. To increase specificity of the detection, the 6xHis-tag was used for Western Blot analysis of the pulled down proteins. Additionally, S. pneumoniae itself was used as cellular beads for a pull down of the same peptide-MBP-His constructs, again followed by analysis with SDS gel and Western Blot.
Sources
1. Chen, C.L., et al., Development of a LytE-based high-density surface display system in Bacillus subtilis. Microb Biotechnol, 2008. 1(2): p. 177-90.
6. Liew, P.X., C.L. Wang, and S.L. Wong, Functional characterization and localization of a Bacillus subtilis sortase and its substrate and use of this sortase system to covalently anchor a heterologous protein to the B. subtilis cell wall for surface display. J Bacteriol, 2012. 194(1): p. 161-75.
11. Manoil, C. and J. Beckwith, A genetic approach to analyzing membrane protein topology. Science, 1986. 233(4771): p. 1403-8.
12. Brickman, E. and J. Beckwith, Analysis of the regulation of Escherichia coli alkaline phosphatase synthesis using deletions and φ80 transducing phages. Journal of Molecular Biology, 1975. 96(2): p. 307-316.
Results
Overexpression of tagged NOX and peptides
Figure 1:SDS-PAGE for the overexpression of NOX compared to the empty vector. Different fractions of two clones (C1, C2) carrying the NOX-insert were compared to a clone carrying the empty vector. Cultures were lysed and centrifuged to separate the supernatant (SN) from the pellet (P). Samples of the cells were taken at different time points (PI = pre-induction, AI = 2h after induction). 20 μl of fractions were loaded.
The protein composition of the two clones show no difference in contrast to the strain carrying the empty vector. A band at around 55 kDa would have been expected for NOX. Thus, the expression of NOX was not successful.
Figure 2:SDS-PAGE of induced (I) and uninduced (UI) strains carrying the peptides C4P, CSP or A5P fused to MBP. Strains carrying the plasmids coding for the His-MBP tagged peptides were induced, lysed and centrifuged to separate the supernatant (SN) from the pellet (P). Samples were taken at different time points (PI = pre-induction, AI= 2h after induction) and uninduced strains serve as an control for expression. The lanes were loaded with 15μl.
The overexpression of MBP-tagged peptides was successful. The supernatant fractions showed a thick band at approximately 40kDa, corresponding to the size of MBP, which was not present in the uninduced samples. A smaller amount of the protein was also present in the lane of the pellet, but the major amount is cytosolic. Since the overexpression of NOX did not work, the planned pull-down of NOX with beads could not be performed. Instead the binding of peptides was tested by applying the His-MBP tagged peptides to S. pneumoniae cells.
Adhesion of peptides to S.pneumoniae – Pulldown with cells
Figure 3:SDS-PAGE of the lysates and the fractions of the incubated S. pneumoniae cells. E. coli cells carrying the plasmids coding for C4P, CSP and A5P were lysed. S. pneumoniae cells were resuspended in the lysate and incubated for 30 minutes, followed by pelleting to separate the supernatant (SP) from the cell pellet (P). 3 μl of sample were applied per lane.
The gel of the SDS-PAGE (Fig. 3) shows strong bands for the lysates at 40kDa, indicating a high amount of the His-MBP tagged peptides. The empty vector shows a relatively low expression of His-MBP. The pellet fractions of the S. pneumoniae cells incubated with the tagged C4P and CSP peptides show light bands at the same height indicating adhesion of the peptides to the cells (Fig. 4, white arrows). Although the cells incubated in buffer alone also show a band at the same height indicating a native protein of that size (Fig. 3, black arrows) the amount of protein is clearly less. To determine whether the band represents the His-MBP tagged peptides, a western blot was performed (Figure 4).
Figure 4: Western-Blots of the lysates and the fractions of the incubated S. pneumoniae cells. Duplicates of the gel from Figure 4 (A) and another gel loaded with 10 μl/ lane (B) were processed by western blot with Anti-His antibodies.
The blot shows a clear signal for the applied lysates and all the pellet fractions of the cells incubated with the peptides, indicating their adhesion to S.pneumoniae. The band for the His-MBP of empty vector is missing (or very weak), which might be due to the lower expression, but one can clearly detect the bands corresponding to the His-MBP in the SDS-PAGE (Fig. 4). Our results strongly indicate that the previously described adhesion of the peptides to S. pneumoniae works. Thus, our BioBricks [http://parts.igem.org/Part:BBa_K1351001 BBa_K1351001], [http://parts.igem.org/Part:BBa_K1351002 BBa_K1351002] and [http://parts.igem.org/Part:BBa_K1351003 BBa_K1351003] should serve as a tool for adhesion to S. pneumoniae.
Killing
A key aspect of our project is the killing module, which enables BaKillus to dispatch pathogens. Therefore, we implement a variety of killing strategies into our chassis.
One of our killing factors is subtilin, a lanthionine-containing antimicrobial peptide. Just like other lantibiotics, it is active against a wide range of Gram-positive bacteria by inhibiting the cell wall synthesis and the formation of membrane pores. The latter leads to the depolarisation of the membrane and thus, to rapid cell death. We decided to use subtilin, as it is natively produced by Bacillus subtilis ATCC6633, a close relative to our chassis. additionally lantibiotics are considered to be an alternative to classical antibiotics (to which many bacteria already developed resistance).
Another killing factor is lysostaphin, a metallo-endopeptidase, which lysates the cell wall of some Staphylococcus species. Since this enzyme is highly specific, and S. aureus is especially sensitive towards lysostaphin, this is an ideal killing strategy for our BaKillus. In addition, lysostaphin shows no signs of toxicity and a very low potential for allergic reactions in first tests on animals and humans.
Since pathogens are often protected by biofilms and thus not very sensitive towards killing agents, dispersin was integrated as an auxiliary device. This glycosaminhydrolase destroys biofilms of many gram-positive and gram-negative bacteria, including S. aureus, making them more susceptible for antibiotics and other pathogen defeating agents.
Both, [http://parts.igem.org/Part:BBa_K802000 lysostaphin] and [http://parts.igem.org/Part:BBa_K802001 dispersin] were developed as BioBricks and tested in B. subtilis by the iGEM Team iGEM12_Lyon_INSA in 2012. We aim to evaluate the effectiveness of these two S. aureus defeating agents.
Subtilin
Subtilin is a small antimicrobial peptide (AMP) which belongs to the class of lanthionine-containing antibiotics (lantibiotics). These are heat-stable, ribosomally synthesized molecules with a molecular weight below 4 kDa. Their main characteristic is the high proportion of unusual amino acids, synthesized by post-translational side-chain modifications of precursor peptides. Most prominent examples are the polycyclic thioether amino acids, lanthionine and β–methyllanthionine and a number of dehydrated amino acids such as dehydroalanine (Dha) and dehydrobutyrine (Dhb).
Lantibiotics are promising candidates for future antimicrobials, as they inhibit the growth of many clinically relevant pathogens comprising even multidrug-resistant bacteria. Moreover, lantibiotics have only low tendency to generate resistance. Both features make them highly attractive for medical applications.
Fig. 1. Schematic representation of the structure of the lantibiotic subtilin. Dha represents a dehydroalanine residue, Dhb represents a dehydrobutirine residue, and Abu represents a dehydrobutirine residue that has formed a thioether β-methyl-lanthionine bridge with a cysteine residue. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Quorum+sensing+control+of+lantibiotic+production%3B+nisin+and+subtilin+autoregulate+their+own+biosynthesis]
The spaBTCSIFEGRK gene cluster
Fig. 2. Organisation of the subtilin biosynthetic gene cluster. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Quorum+sensing+control+of+lantibiotic+production%3B+nisin+and+subtilin+autoregulate+their+own+biosynthesis]
As true for many other lantibiotics, the genes for the subtilin biosynthesis are clustered. For subtilin, there is even a reasonable arrangement within the cluster. The genes spaBTC play a role for the posttranslational modifications and the transport of subtilin. They are regulated by their own promotor PspaB and polycistronically transcribed. spaS encodes the propeptide, which is derived from a short monocistronic mRNA. The next transcription entity, spaIFEG, is coding for the immunity, whereas spaRK encodes a two-component-system that plays an important role for the regulation. What is missing in comparison to other lantibiotic gene clusters is a specific protease (encoded by lanP) that cleaves off the leader sequence. In Bacillus subtilis, this task is accomplished by unspecific extracellular proteases.
Table 1: The role of the different proteins of the spa-locus
Protein
Annotation
Function
Modification
SpaB
Hydratase
Dehydration of selected serines and threonines
SpaT
NisT-type ABC-transporter
Export of newly synthesized AMPs
SpaC
Cyclase
Thioether ring formation
Peptide
SpaS
Antimicrobial peptide (AMP)
Acts as antimicrobial agent
Immunity
SpaI
Lipoprotein
Providing self-protection by binding AMP
SpaFEG
LanFEG-type ABC-transporter
Providing resistance by exporting AMPs from cytoplasmic membrane to culture supernatant
Regulation
SpaRK
Two-component system
Histidine-kinase and response regulator (quorum sensing mechanism)
Self-protection from subtilin
Of course, the producer needs to be immune against the antimicrobial agent it produces. B. subtilis ATCC6633 protects itself against subtilin by two mechanisms that both act independently and confer some level of resistance, however full resistance is only achieved when both mechanisms are active. SpaI is a membrane-anchored lipoprotein. It is suggested that it binds the antimicrobial peptide and by this keeps it away from the membrane. SpaFEG is a LanFEG-like ABC-transporter that works by exporting subtilin from the cytoplasmic membrane to the culture supernatant.
Dual regulation of subtilin biosynthesis and immunity
Fig. 3. Dual control of subtilin biosynthesis and immunity. [http://www.ncbi.nlm.nih.gov/pubmed/11972779]
Subtilin biosynthesis and immunity in B. subtilis ATCC6633 are subject to a dual control mechanism.
To begin with, subtilin production is positively regulated by sigma factor H (SigH). SigH itself is repressed by the transition state regulator AbrB during exponential growth phase. Thus, subtilin production is highest at the transition to stationary phase. Moreover, when a threshold level of subtilin concentration is reached in the extracellular space, the peptide acts as a pheromone. Subtilin activates the two-component system SpaRK, consisting of a histidine kinase and a response regulator, which in turn induces expression of spaBTC, spaS and spaIFEG. This dual control mechanism allows the coordination of subtilin biosynthesis with the physiological state of the cell.
Mode of action
Lantibiotics are active against a wide range of Gram-positive bacteria including multidrug-resistant pathogens. Some lantibiotics have a dual mode of action, subtilin is proposed to be among them. Subtilin forms a complex with the cell wall precursor lipid II, whereby the pyrophosphate moiety may play a key role for target recognition. Thereby, the cell wall biosynthesis is inhibited. Furthermore, the complexes aggregate and form a pore in the bacterial membrane by using lipid II as a docking molecule. This leads to a depolarisation of the membrane potential, the efflux of cytoplasma and in turn to rapid cell death. Just like nisin, which is highly similar, subtilin is still active in the nanomolar range and thus serves excellently as alternative killing strategy against multidrug-resistant pathogens.
Fig. 4. Proposed mechanism of pyrophosphate-mediated target engagement by the lanthionine antibiotic subtilin. Membrane breaches occur in a lipid II-mediated fashion and cell wall synthesis is impeded through engagement of pyrophosphate-containing intermediates into complexes. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Molecular+Mechanism+of+Target+parisot]
Lysostaphin
targeted pentaglycinbridge in the cellwall of some Staphylococcus species [B1]
Lysostaphin is a murein-hydrolase, which is naturally produced by Staphylococcus simulans biovar staphylolyticus in order to defeat other, competing Staphylococcus species. It cleaves specifically the pentaglycinbridge between the tetrapeptides of the peptidoglycan in the cell wall. In addition to killing the cells, lysostaphin also dissolves the biofilms of lysostaphin-sensitive bacteria. [http://www.ncbi.nlm.nih.gov/pubmed/19149589 [B1]]
This targeted pentaglycinbridge is a feature of the cell wall of some Staphylococcus species, leading to the high specificity of lysostaphin against S. carnosus, S. epidermidis and S. aureus, which is particularly sensitive towards lysostaphin. http://www.ncbi.nlm.nih.gov/pubmed/18607587 B2
The immunity of S. simulans is accomplished by substitution of the glycine-residues in the cell wall by serine which is mediated by the immunity factor Lif [http://www.ncbi.nlm.nih.gov/pubmed/1914958 [B1]] .
maturation of Lysostaphin [B1]
The pre-pro-lysostaphin consists of a signal peptide to mediate the export, 15 tandem repeats of 13 amino acids length and two protein domains: the peptidase-domain and the C-terminal targeting domain. The signal peptide is cleaved during the export, the tandem repeats are cleaved by an additionally secreted cysteine protease. This repeats are not necessary for correct protein folding or maturation of the protein, they just inhibit protein activity. Once cleaved off, the maturated protein is 4.5 fold more active. [http://www.ncbi.nlm.nih.gov/pubmed/1914958 [B1]]
Because of its promising attributes, the utilization of lysostaphin as a coating for implants [http://www.ncbi.nlm.nih.gov/pubmed/21709102 [B3] ] and treatment of S. aureus in the nasal area via cream [http://www.ncbi.nlm.nih.gov/pubmed/12709327[B4]] is currently in the focus of medical research.
Dispersin
DispersinB (DspB) is a biofilm-dissolving enzyme, specifically a 1,6-beta-N-acetyl-glucosaminidase. It is produced by Aggregatibacter actinomycetemcomitans, a pathogen which causes aggressive forms of Parodontitis. [http://www.ncbi.nlm.nih.gov/pubmed/23103508 [B5]] In its natural habitat, A. actinomycetecombitans uses this enzyme to release single cells from the biofilm in order to colonize new habitats. [http://www.ncbi.nlm.nih.gov/pubmed/15878175[B6]] DspB is specific towards its substrate, PNAG, (PGA in E. coli), which is an important component of the extracellular matrix and which can make up to 90% of the dry weight of a biofilm. [http://www.ncbi.nlm.nih.gov/pubmed/15576769 [B7]] The process of dissolving biofilms is accomplished by cleaving monosaccharide-residues from the polysaccharide, beginning at the non-reducing end of the PNAG. [http://www.ncbi.nlm.nih.gov/pubmed/15878175[B6]] This glycosamin-hydrolase has a typical TIM-barrel-structure, consisting of 8α- and 8β-barrels, with a large cavity in the middle, which is considered to be the substrate-binding pocket. [http://www.ncbi.nlm.nih.gov/pubmed/23103508 [B5]]
Proposed mechanism of reaction [http://www.ncbi.nlm.nih.gov/pubmed/17949435 [B8]
The currently proposed mechanism of reaction suggests a substrate assisted nucleophilic attack (see chart below) [http://www.ncbi.nlm.nih.gov/pubmed/17949435[B8]]
Barrel structure of DspB [http://www.ncbi.nlm.nih.gov/pubmed/15878175[B6]
DspB is active against many bacteria, both gram-positive and gram-negative, and shows some very promising features for its use in medical devices. It can prevent the growth of biofilms in coated catheters if used in combination with triclosan, and can be used to clear medical devices of biofilms. [http://www.ncbi.nlm.nih.gov/pubmed/19447791[B9]]
Sources:
[B1] M.C.F. Bastos, H. Ceotto1, M.L.V. Coelho and J.S. Nascimento: Staphylococcal Antimicrobial Peptides: Relevant Properties and Potential Biotechnological Applications in Current Pharmaceutical Biotechnology (2009) S. 38-61
[B2] Jaspal K. Kumar: Lysostaphin: an antistaphylococcal agent in Appl Microbiol Biotechnol (2008) S.555-561 )
[B3] Rohan Satishkumar, Sriram Sankar, Yuliya Yurko, Amy Lincourt, John Shipp, B. Todd Heniford and Alexey Vertegel: Evaluation of the Antimicrobial Activity of Lysostaphin-Coated Hernia Repair Meshes in Antimicrobial Agents and Chemotherapy (2011)
[B4] John F. Kokai-Kun, Scott M. Walsh, Tanya Chanturiya, and James J. Mond: Lysostaphin Cream Eradicates Staphylococcus aureus Nasal Colonization in a Cotton Rat Model in Antimicrobial Agents and Chemotherapy, 47 (2003)
[B5] Erika Fazekas, Lili Kandra, Gyongyi Gyemant: Model for b-1,6-N-acetylglucosamine oligomer hydrolysis catalysed by DispersinB, a biofilm degrading enzyme, in Carbohydrate Research 363 (2012), S. 7-13
[B6] N. RamasubbuL. M. Thomas, C. Ragunath and J. B. Kaplan: Structural Analysis of Dispersin B, a Biofilm-releasing Glycoside Hydrolase from the Periodontopathogen Actinobacillus actinomycetemcomitans, in Journal of Molecular Biology 340 (2005) S. 475-486
[B7] Jeffrey B. Kaplan, Kabilan Velliyagounder, Chandran Ragunath, Holger Rohde,
Dietrich Mack, Johannes K.-M. Knobloch, and Narayanan Ramasubbu: Genes Involved in the Synthesis and Degradation of Matrix Polysaccharide in Actinobacillus actinomycetemcomitans and Actinobacillus pleuropneumoniae Biofilms, in JOURNAL OF BACTERIOLOGY, 186 (2004) S.8213-8220
[B8] Suba G. A. Manuel, Chandran Ragunath, Hameetha B. R. Sait, Era A. Izano, Jeffrey B. Kaplan and Narayanan Ramasubbu: Role of active-site residues of dispersin B, a biofilm-releasing b-hexosaminidase from a periodontal pathogen, in substrate hydrolysis, in The FEBS journal (2007)
[B9] Darouiche RO, Mansouri MD, Gawande PV, et al. Antimicrobial and antibiofilm efficacy of triclosan and DispersinB combination. J Antimicrob Chemother 2009; 64: 88-93
Subtilin
Analysis of subtilin impact on pathogens
To prove that subtilin has an inhibiting impact on pathogens and thus, is convenient as a BaKillus killing strategy, different growth and killing assays were performed. These experiments included spot-on-lawn-assays, growth and killing curves and luminescence assays and were conducted for Streptococcus pneumoniae and with the kind support of the iGEM Team Groningen also with Staphylococcus aureus sp., including MRSA. Protocols to the specific assays can be found here.
Heterologous expression
As our working horse Bacillus subtilis 168 is closely related to the subtilin producer Bacillus subtilis ATCC6633, one approach for subtilin production is the heterologous expression by transferring the complete spaBTCSIFEGRK gene cluster into B. subtilis. In this case, the native regulation of subtilin biosynthesis and immunity, the two-component system spaRK, is maintained. Moreover, the transition state regulation should be similar for both organisms.
The BioBrick approach
The SynBio approach of this subproject is the standardization of the subtilin gene cluster. Therefore, the gene cluster was subdivided into BioBricks according to their function and maintaining the transcription entities. However, in contrast to the classical heterologous expression, the BioBricks are standardized according to the RFC10 or the RFC25 standard, respectively.
Moreover, gene expression and subtilin production will no longer be controlled by the native regulation system, but are rather in dependance on promotors, activated in a quorum sensing dependent matter.
Lyostaphin
The BioBrick [http://parts.igem.org/Part:BBa_K802000 K802000], built by the iGEM Team iGEM12_Lyon_INSA, was kindly sent by the team Insa-Lyon. Via PCR-amplification, the actual lyosostaphin-gene was amplified, adding the restriction sites required for the RFC25.
The coding sequence was cloned together with the promoter Pxyl ([http://parts.igem.org/wiki/index.php?title=Part:BBa_K1351039 BBa_K1351039]) into the plasmid pBS1C ([http://parts.igem.org/wiki/index.php?title=Part:BBa_K823023 BBa_K823023]). After transformation into B. subtilis, the iGEM-team Groningen will evaluate the effectiveness of lysostaphin, produced by B. subtilis against S. aureus via spot on lawn test. This test will be conducted with living cells as well as with cell lysate in order to evaluate whether the lysostaphin is secreted into the supernatent by B.subtilis or not.
Dispersin
The BioBrick [http://parts.igem.org/Part:BBa_K802001 K802001] built by the iGEM Team iGEM12_Lyon_INSA, was kindly sent by the Team Insa-Lyon. The original DspB contains an AgeI restriction site, which was deleted via site directed mutagenesis by overlaping extension PCR in order to make the gene compatible with the Freiburg standard RFC 25.
Overhangs with RFC 25 compatible restriction sites where added during this PCR and the PCR-product was cloned into the pCRII-Topo-vector.
After sequence confirmation, the DspB will be cloned into pSB1C3 in order to be sent in as a BioBrick. The His-Tag will be added added C- and N-terminally, and a copy of each of the His-tagged-constructs, and one copy without His-tag will be cloned together with the promoter Pxyl ([http://parts.igem.org/wiki/index.php?title=Part:BBa_K1351039 BBa_K1351039]) into the vector pBS1C ([http://parts.igem.org/wiki/index.php?title=Part:BBa_K823023 BBa_K823023] ). The transformation into B. subtilis will follow.
In order to test the biofilm dissolving abilities of this recombinant B. subtilis, biofilms of E. coli Nissle 1917, an excellent biofilm forming bacteria with GRAS-status, will be grown in 96 well plates. The biofilms will be dyed with crystalviolett and living B. subtilis cells as well as cell lysate will be transferred into the wells.
If biofilm-destruction takes places, the crystalviolett will vanish by carefully washing the plates.
Additionally, an expression control will be conducted via Western Blot.
Subtilin
Subtilin impact on Streptococcus pneumoniae
First of all, a growth curve for S. pneumoniae was recorded to learn about the growth behavior of this organism. It was measured in the plate reader in 100 µl THB broth at 37 °C without shaking and measurement was taken every 10 min. The mean value of 10 measurements were determined and plotted.
Fig. 1. Growth curve of S. pneumoniae measured in the plate reader in 100 µl THB broth.
Fig. 1. The spot-on-lawn assay shows a clear halo around the B. subtilis ATCC6633 spot. No clearing zone is visible around B. subtilis W168.
As expected, S. pneumoniae shows rapid growth during its exponential growth phase. It reaches its maximal OD600 just under 5 hours. In contrast to other bacteria, for S. pneumoniae, there is no plateau during stationary phase, as autolysis of the cells starts and the OD600 decreases again.
As S. pneumoniae is a target of the BaKillus killing strategies, a spot-on-lawn-assay should reveal the inhibitory impact of subtilin. Therefore, spots of the B. subtilis W168 wild type and the subtilin-producer B. subtilis ATCC6633, respectively, were spotted on a S. pneumoniae lawn. As depicted in figure XY, the subtilin producer significantly inhibits the growth of S. pneumoniae. In contrast, B. subtilis W168 wild type does not show inhibitory impact. The experiment was performed three times and the mean value and the standard deviation are illustrated in the graph below.
Fig. 1. Bar graph .
Subtilin impact on Staphylococcus aureus
Moreover, the impact of subtilin on Staphylococcus aureus was tested in collaboration with iGEM Team Groningen, as they have access to S2 laboratories, in which S. aureus and even multidrug-resitant species are handled. A member of Team Groningen kindly performed spot-on-lawn assays with B. subtilis W168 wild type and the subtilin-producer B. subtilis ATCC6633 on different S. aureus species. The tested strains were CAL, NWZ (both MRSA, obtained at the UMCG hospital) and CECT240 (Staphylococcus aureus subsp. aureus, Rosenbach 1884). Strains were plated out in soft agar and spots from overnight cultures of Bacillus subtilis grown in either complex medium (LB) or defined medium (SMM) were added on top.
Fig. 1. Spot-on-lawn assay with the subtilin producer and on three different S. aureus lawns
After incubation for 24 h at 37 °C, halos could be detected for all spots of the subtilin producer. The exact results are shown in the chart below. However, the spots of the B. subtilis W168 culture did not inhibit the growth of any S. aureus strains (no pictures provided).
Fig. 1..
Heterologous expression
The aim of this approach was to transfer the complete subtilin gene cluster into our working horse Bacillus subtilis W168 by maintaining the native regulation mainly mediated by the spaRK two-component system. So far, the 12 kb-locus is assumed to be transferred into our Bacillus wild type but only half of the locus is sequenced. Unfortunately, no subtilin production could be ascertained. This could be due to an incorrect sequence or the fact that the native regulation of B. subtilis ATCC6633 does not work in our wild type. Our next steps are the full sequencing of the putative spa-gene cluster and an attempt to transfer it into B.subtilis W168 ΔabrB, a mutant that lacks the repressing transition state regulator.
The BioBrick approach
This approach aims to "BioBrick" and by this standardize the subtilin gene cluster according to its transcriptional entities. In contrast to the heterologous expression, the BioBricks will be under quorum sensing dependent regulation.
Modification & Transport
The BioBrick [http://parts.igem.org/Part:BBa_K1351041 BBa K1351041], encoding SpaBTC, is mainly responsible for the modification and the export of the subtilin propeptide. After the removal of 6 BioBrick restriction sites within the three genes, it is now in the RFC10 BioBrick standard.
This BioBrick was accomplished just before WikiFreeze, so that no further evaluation was possible so far.
Antimicrobial peptide
[http://parts.igem.org/Part:BBa_K1351012 BBa K1351012] and [http://parts.igem.org/Part:BBa_K1351013 BBa K1351013] are coding for SpaS, the subtilin pro-peptide. Their main difference are their overhangs, one being in RFC25, which allows the tagging or translational fusion of [http://parts.igem.org/Part:BBa_K1351012 BBa K1351012], whereas the other can be used according to the RFC10 BioBrick standard. Unfortunately none of them could be evaluated so far, as the development of the immunity BioBrick as well as of the modification and export BioBrick were required beforehand.
Immunity
The immunity against subtilin ([http://parts.igem.org/Part:BBa_K1351014 BBa K1351014]), was - just like the spaS BioBricks - submitted to the iGEM parts registry. Self-protection is mediated by SpaIFEG, a membrane-anchored lipoprotein and an ABC-transporter.
Fig. 1. Supernatant-in-lawn assay shows smaller halo diameters for B. subtilis with BioBRick-acquired immunity.
The part was evaluated with a variation of an spot-on-lawn assay. In this case, holes were cut out of agar plates on which either B. subtilis W168 wild type or B. subtilis W168 amyE::Pxyl_spaIFEG were plated. The holes were then filled with different amounts of sterile supernatant from overnight cultures of W168 or ATCC6633, respectively. The xylose-containing plates were incubated at 37 °C for 24 h and resulting halo diameters were measured. The supernatant derived from the negative control (W168) did not cause any growth inhibition to neither the wild type, nor to the strain who carries the immunity BioBrick (Figure XY). The subtilin-containing supernatant from B. subtilis ATCC6633 however, was able to inhibit the growth of both bacterial lawns. For the lowest amounts (32 µl), no significant difference between the halo diameters could be determined. The larger the amount of supernatant, and presumably, the higher the amount of subtilin in there, the bigger the zones of inhibition. For the largest volume (128 µl), a two-sided T-test could determine the p-value below 0.1 (p=0,007762603) and by this prove the functionality of this BioBrick. This is a major step for this project, as the immunity is the base for any strain which produces antimicrobial peptides. Now further steps can be taken and the remaining BioBricks can be evaluated.
Fig. 1..
The graph shows wildtype Bacillus subtilis, the ΔsdpI mutant
Hi there!
Welcome to our Wiki! I'm BaKillus, the pathogen-hunting microbe, and I'll guide you on this tour through our project. If you want to learn more about a specific step, you can simply close the tour and come back to it anytime you like. So let's start!
What's the problem?
First of all, what am I doing here? The problem is, pathogenic bacteria all around the world are becoming more and more resistant against antimicrobial drugs. One major reason for the trend is the inappropriate use of drugs. With my BaKillus super powers, I want to reduce this misuse and thus do my part to save global health.
Sensing of pathogens
To combat the pathogenic bacteria, I simply eavesdrop on their communication. Bacteria talk with each other via quorum sensing systems, which I use to detect them and trigger my responses.
Adhesion
The more specific and effective I can use my powers, the lower the danger is of provoking new resistance development. So I catch pathogens whenever I get hold of them and stick to them until my work is done.
Killing
Talking about my work - killing pathogens is finally what I am made for. In response to quorum sensing molecules of the pathogens, I export a range of antimicrobial substances leading to dissipation of biofilms and the killing of the targeted bacteria.
Suicide switch
When the job is done and all the bad guys are finished, you don't need a super hero anymore. So after fulfilling my work I say goodbye to the world by activating my suicide switch.
Application
Of course I'm not only a fictional hero, but a very real one. In two different prototypes, I could be used for diagnosis or treatment of pathogen-caused diseases. However, there is still a whole lot of regulational and economical questions that have to be answered before.
"
